1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Glaukos iStent® Trabecular Micro-Bypass Stent (Models: GTS-100R, GTS-100L) and Inserter (GTS-100i) - P080030. 2012. www.accessdata.fda.gov/cdrh_docs/pdf8/P080030a.pdf; Accessed 2 Sep 2019.
2. FDA/AGS Workshop on supporting innovation for safe and effective minimally invasive glaucoma surgery. 2014. http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm382508.htm; Accessed 2 Sep 2019.
3. Premarket studies of implantable minimally invasive glaucoma surgical devices - guidance for industry and Food and Drug Administration staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-studies-implantable-minimally-invasive-glaucoma-surgical-migs-devices; Accessed 2 Sep 2019.
4. Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61–68.
5. Hunter NL, O’Callaghan KM, Califf RM. Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA 2015;314:2499–500.